Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the loss of adaptive immune tolerance to nucleic acid-containing antigens. The resulting autoantibodies form immune complexes that promote inflammation and tissue damage. Defining the signals that drive pathogenic autoantibody production is an important step in the development of more targeted therapeutic approaches for lupus, which is currently treated primarily with non-specific immunosuppression. Here, we review the contribution of Bruton's tyrosine kinase (Btk), a component of B and myeloid cell signaling pathways, to disease in murine lupus models. Both gain-and loss-of-function genetic studies have revealed that Btk plays multiple roles in the production of autoantibodies. These include promoting the activation, plasma cell differentiation, and class switching of autoreactive B cells. Small molecule inhibitors of Btk are effective at reducing autoantibody levels, B cell activation, and kidney damage in several lupus models. These studies suggest that Btk may promote end-organ damage both by facilitating the production of autoantibodies and by mediating the inflammatory response of myeloid cells to these immune complexes. While Btk has not been associated with SLE in GWAS studies, SLE B cells display signaling defects in components both upstream and downstream of Btk consistent with enhanced activation of Btk signaling pathways. Taken together, these observations indicate that limiting Btk activity is critical for maintaining B cell tolerance and preventing the development of autoimmune disease. Btk inhibitors, generally well-tolerated and approved to treat B cell malignancy, may thus be a useful therapeutic approach for SLE.
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Btk AnD MOUSe LUPUS MODeLS

Btk is Required for Autoantibody Production and Pathogenesis in Many Lupus Models
The xid mutation has long been known to reduce autoantibody levels in several murine lupus models, including NZB × NZW (31), BXSB (32), MRL.lpr (33) , motheaten (34) , and Gld (35) . Renal disease was also prevented and survival improved by the xid mutation in NZB × NZW (31), BXSB (32) , and MRL.lpr (33) mice.
The subsequent finding that Btk is a B cell signaling molecule suggested that enhanced B cell activation through Btk underlies autoantibody production in lupus models. This was tested using mice lacking B cell inhibitory signaling molecules. BCR signaling is normally limited by inhibitory receptors such as FcγRIIb, CD22, SiglecG, PIR-B, and CD72. The ITIMs of these receptors are phosphorylated by the tyrosine kinase Lyn, which results in the recruitment and activation of inhibitory phosphatases, such as SHIP and SHP-1 [reviewed in Ref. (36) (37) (38) ]. B cell-specific deletion of Lyn, SHIP, or SHP-1 leads to B cell hyper-responsiveness and lupus-like autoimmune disease in mice (39) (40) (41) . Mutations in inhibitory receptors result in milder autoimmunity, likely due to some degree of redundancy among them (42) (43) (44) (45) (46) (47) . Several of these inhibitory pathways target activating signals mediated by Btk (14, 16, 48) .
Either the xid mutation (49) Taken together, the following observations suggest that Btk acts primarily in the periphery, rather than the bone marrow, to drive a loss of B cell tolerance. In Btk −/− mice carrying an anti-DNA Ig transgene, anti-DNA B cells are present in the periphery but do not produce antibodies in vivo (26) . Single cell repertoire analysis of new emigrant B cells (recently arrived in the periphery from the bone marrow) from XLA patients revealed a higher frequency of autoreactive B cells than in healthy controls (58) . This indicates that Btk signaling may actually promote central tolerance, and that Btk-deficiency does not abrogate autoimmunity simply by preventing autoreactive B cells from reaching the periphery. Furthermore, immunoglobulin transgenic mouse models and analysis of XLA patient B cell repertoires have shown that receptor editing is independent of Btk (58-60). A role for Btk in the loss of peripheral B cell tolerance is highlighted by both loss-of-function and overexpression studies. Btk is required for autoimmunity in Lyn −/− mice (49-52), which have intact central tolerance but develop autoantibodies due to a breach of peripheral tolerance (61, 62) . Mice overexpressing Btk in mature B cells and myeloid cells, but not at earlier stages of B cell development in the bone marrow, develop autoimmunity (56) . (50, 52) , suggesting that in the absence of Lyn-mediated inhibitory signaling, low levels of Btk are able to transmit some aspects of BCR signals efficiently. However, Lyn −/− Btk lo mice do not develop autoantibodies or autoimmune disease (51, 52) . Similarly, although Btk-deficient anti-DNA transgenic mice do not produce autoantibodies (26), Btk is not required for B cells from these mice or from AM14 rheumatoid factor (RF) transgenic mice to proliferate in response to nucleic acid-containing antigens (26, 63) . Such autoantigens, common in lupus, activate B cells via both the BCR and nucleic acid-sensing TLRs (1). Thus, Btk has additional functions beyond transmitting proliferative signals from the BCR and TLRs that promote the loss of B cell tolerance.
Btk Contributes to Autoantibody Production beyond
Btk Drives Plasma Cell (PC) Accumulation
Accumulation of antibody-secreting PCs in the periphery is characteristic of SLE patients (64, 65) and murine lupus models, including Lyn −/− mice (51, (66) (67) (68) (69) (70) (71) (72) (73) (74) Btk lo mice have decreased serum IL-6 levels and a reduced frequency of myeloid cells expressing IL-6 in response to LPS compared to Lyn −/− mice (51). B cellderived IL-6 is also increased in Lyn −/− mice (70), and is required in other models for the formation of autoreactive germinal centers, in which class switching occurs (81, 82) . Btk is required for the upregulation of IL-6 in B cells in response to synergistic BCR and TLR9 signaling (27) , and B cells overexpressing Btk express more IL-6 (57). Btk also promotes expression of IL-21, a Tfh-derived cytokine, in Lyn −/− mice. This likely occurs via IL-6 as splenocytes from both Lyn 
Btk and Innate-Like B Cells
Bruton's tyrosine kinase is expressed in B1a and marginal zone (MZ) B cells. These innate-like B cells may have both pathogenic and protective roles in autoimmune disease. The relative importance of Btk in these specific roles is not clear.
B1a cells are found predominantly in the peritoneal cavity, have a repertoire enriched in polyreactivity (87, 88) , and are increased in several lupus models (41, 42, (88) (89) (90) . Whether they are elevated in Lyn −/− mice is controversial (52, 72, 91, 92) . They secrete protective IgM autoantibodies (93) and the anti-inflammatory cytokine IL-10 (94, 95). In some cases they do not contribute to pathogenic autoantibodies (96), but they can produce IgG autoantibodies and interact with T cells in a pro-inflammatory manner in some lupus models (88, 97, 98 Marginal zone B cells are also enriched in autoreactivity (99) (100) (101) . Whether they contribute to pathogenic autoantibodies in lupus is model-dependent (71, (101) (102) (103) (104) (105) (106) (107) , and may be modulated indirectly by alterations in splenic architecture in some strains. Btk is not required for MZ B cell development, but it controls the positive selection of particular B cell specificities into the MZ compartment (108) . How this affects autoimmunity is not clear. Skewing of autoreactive B cells to the MZ is promoted by Btk in the 56R anti-DNA immunoglobulin transgenic model (26) and in NOD mice (109), a model of type I diabetes, but RF B cells carrying the xid mutation are enriched in the MZ relative to their wild-type counterparts (63) .
Btk inhibitors Are effective in Mouse Lupus Models
The genetic evidence described above suggests that small molecule inhibitors of Btk could be an effective therapy for SLE. Preclinical studies with several inhibitors in multiple mouse models suggest that this may indeed be the case ( Table 1 ) (110) (111) (112) (113) (114) (115) (116) (117) . Kidney damage was ameliorated in all cases and survival increased when measured. Btk inhibitors diminished B cell activity, as measured by reduced CD69 expression, PC frequencies, and/or germinal center B cell frequencies. Autoantibodies were also decreased, although in some cases not all specificities or isotypes were affected. Interestingly, kidney damage was prevented even in the few situations where IgG autoantibodies were not significantly reduced. This indicates that Btk has roles in lupus pathogenesis beyond its contribution to the loss of B cell tolerance. Btk inhibitors were effective in anti-GBM models of kidney disease, which measure only the effector phase of kidney inflammation and damage and do not depend on autoantibody production (113, 117) . Btk inhibitors impair pro-inflammatory FcR responses of myeloid cells in vitro (111) (112) (113) (116) (117) (118) (119) , suggesting that Btkdependent effector functions of myeloid cells may contribute to end-organ damage in vivo. However, Btk-deficiency in myeloid cells can have pro-or anti-inflammatory effects dependent on cell type and stimulus (120) (121) (122) (123) (124) (125) (126) (127) (128) (129) (130) (131) (132) (133) (134) (135) , and off-target effects of inhibitors cannot be ruled out (136) . For instance, the Btk inhibitor ibrutinib also inhibits Itk (137), a related Tec kinase which has important functions in T cells. Further studies of the relative roles of B and myeloid cell-expressed Btk in lupus pathogenesis would be facilitated by the development of cell type-specific Btk knockout mice.
Btk in HUMAn AUTOiMMUniTY
While polymorphisms in Btk have not been identified in GWAS studies of SLE or other autoimmune diseases, several lines of evidence suggest that increased Btk activity may be associated with autoantibody production in humans. Increased Btk expression and phosphorylation was observed in B cells from rheumatoid arthritis patients (138, 139) , correlating with RF antibodies among RF-positive patients (139) and enriched in anti-citrullinated protein antibody-positive patients (138) . Similarly, increased Btk expression and phosphorylation correlated with RF antibodies in Sjogren's syndrome patients (138) . The frequency of Btk + cells in the peripheral blood of SLE patients has been reported to correlate with disease activity, anti-dsDNA antibodies, proteinuria, and C3 levels (140), but whether this reflects changes in Btk signaling or cell subset distribution is unclear.
Several SLE-associated signaling defects and polymorphisms likely result in increased activity of Btk signaling pathways in B cells. Reduced expression of PTEN, which counteracts PI3K, has been observed in human lupus B cells (141) . Btk activation and function require the binding of its PH domain to the product of PI3K in the plasma membrane (11) (12) (13) (14) , and PTEN haploinsufficiency enhances the efficiency of Btk signaling in mice (142) . The autoimmune phenotype in Lyn −/− mice is mediated by excessive Btk activity in mice (49-52, 76, 80) . Polymorphisms in Lyn are associated with SLE (143, 144), and reduced Lyn expression is observed in B cells from a subset of SLE patients (145) (146) (147) . Expression of CSK, an inhibitor of Lyn, is increased by an SLEassociated polymorphism in the CSK gene. B cells carrying this SNP have reduced Lyn activity and increased responses to BCR signaling (148) . Finally, several polymorphisms in Ets1 are associated with SLE, and Ets1 expression is reduced in PBMCs from SLE patients [reviewed in Ref. (149)]. Btk promotes the accumulation of autoreactive PCs in Lyn −/− mice by downregulating Ets1 (76) .
COnCLUSiOn
Genetic studies demonstrate multiple roles for Btk in the development of murine lupus (Figure 1) , including promoting the activation, differentiation, and class switching of autoreactive B cells. Btk inhibitors are effective at reducing autoantibodies and/or autoimmune symptoms in mouse lupus models and may act in both B and myeloid cells to exert these effects. In humans, several components of Btk signaling pathways are altered in B cells from lupus patients, and Btk expression and activation is elevated in B cells from other autoimmune diseases. Btk has dose-dependent effects on B cell activation and autoantibody production as illustrated by the phenotypes of Btk lo and Btk-overexpressing mice. Such a rheostat effect of Btk (150) is supported by recent structural analysis indicating that Btk has graded degrees of activity (151) , and suggests that partial inhibition of Btk may have significant functional consequences. Btk may thus be a useful therapeutic target for SLE. The Btk inhibitor ibrutinib is well tolerated and approved for treatment of several B cell malignancies (152, 153) , and second generation, more specific inhibitors such as acalabrutinib are promising (154, 155) . The use of these and other Btk inhibitors in B cell malignancy will be informative with respect to potential off-target and side effects (156, 157) that might be encountered in the context of autoimmune disease.
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